NCT04414540View on ClinicalTrials.gov

Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Metformin Extended Release Oral Tablet

Metformin ER starting dose 1000mg daily Metformin ER escalation dose 2000mg daily

DRUG

Pembrolizumab

Pembrolizumab q 3 weeks

Trial Locations (1)

45219

University of Cincinnati Medical Center, Cincinnati

All Listed Sponsors
collaborator

American Cancer Society, Inc.

OTHER

lead

Trisha Wise-Draper

OTHER